The drugs concerned – donanemab and lecanemab – have been widely hyped as supposed breakthroughs for slowing early-stage Alzheimer’s. However, the UK National Health Service (NHS) spending watchdog concluded that the treatments only delay disease progression by four to six months, deeming this insufficient to justify the projected annual costs of up to £1 billion ($1.35 billion).
There are also worrying safety issues with both of these drugs. Research published in 2024 found that lecanemab can potentially triple a patient’s risk of death. Patients taking the drug have suffered from brain swelling and bleeding, with as many as 1 in 10 experiencing these problems in clinical trials. The side effects of donanemab are very similar.
To read how research supports the use of vitamin C supplementation for the prevention and treatment of Alzheimer’s disease, see this article on our website.
To learn how studies carried out by scientists at the Dr. Rath Research Institute have confirmed that natural compounds show promise in tackling Alzheimer’s disease, see this article on our website.
Vitamin C Levels Linked to Respiratory Infections in Children and Adolescents
June 27, 2025Purdue Pharma to Pay $7.4 Billion in Opioid Lawsuit Settlement
June 27, 2025UK National Health Service Rejects Costly ‘Low Benefit’ Alzheimer’s Drugs
News
The UK’s state-run health service says it will not offer two new treatments for Alzheimer’s disease, citing high costs and “too small” benefits.
[Source: medicalxpress.com]
[Image source: Adobe Stock]
Comment
The drugs concerned – donanemab and lecanemab – have been widely hyped as supposed breakthroughs for slowing early-stage Alzheimer’s. However, the UK National Health Service (NHS) spending watchdog concluded that the treatments only delay disease progression by four to six months, deeming this insufficient to justify the projected annual costs of up to £1 billion ($1.35 billion).
There are also worrying safety issues with both of these drugs. Research published in 2024 found that lecanemab can potentially triple a patient’s risk of death. Patients taking the drug have suffered from brain swelling and bleeding, with as many as 1 in 10 experiencing these problems in clinical trials. The side effects of donanemab are very similar.
To read how research supports the use of vitamin C supplementation for the prevention and treatment of Alzheimer’s disease, see this article on our website.
To learn how studies carried out by scientists at the Dr. Rath Research Institute have confirmed that natural compounds show promise in tackling Alzheimer’s disease, see this article on our website.
Dr. Rath Health Foundation
Related posts
Study Helps Explain Vitamin C’s Extraordinary Power to Reverse Skin Ageing
Read more